Quantcast

BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases—Reply

Research paper by Margonis G, Andreatos N, Weiss MJ.

Indexed on: 23 Dec '18Published on: 01 Dec '18Published in: JAMA surgery



Abstract

In Reply We thank Moretto et al for their interest in our study. As the authors correctly suspected, only a small fraction of the patient population (7 patients) received preoperative fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI); the introduction of this regimen is a fairly recent development that is not well represented in our cohort, which stretches back to 2000. Moreover, only 1 patient treated with FOLFOXIRI had a non-V600E BRAF mutation while the remaining 6 had V600E BRAF mutations, leaving little room for codon/point-specific stratification.